APTX Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.

$3.10
As of 06/18/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  68,173,736
Average volume:  2,505,262
Market cap:   $221,564,642
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03836N103
ISIN:        US03836N1037
Sedol:      BFXGKR6

---

Valuation   (See tab for details)

---

PE ratio:   -5.55
PB ratio:   1.39
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%